Cardarine (GW-501516) vs Survodutide
A side-by-side research comparison of Cardarine (GW-501516) and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardarine (GW-501516) | Survodutide |
|---|---|---|
| Full name | GW-501516 (Cardarine, Endurobol) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Discontinued in development (safety concerns; banned in sport) | Phase 3 Clinical Trial |
| Mechanism | Activates the PPAR-delta nuclear receptor, shifting cells toward burning fat for fuel and upregulating genes involved in fatty-acid oxidation and endurance metabolism. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 453.50 Da | 4,500 Da (approximate) |
| Half-life | ~20-24 hours | 5-7 days |
| Bioavailability | Oral | High (SubQ) |
| Typical dose | Commonly cited 10-20 mg/day (research) | 0.6-6.0 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral | Subcutaneous |
Cardarine (GW-501516) reported benefits
- Increased endurance (research claims)
- Enhanced fat oxidation
- No hormonal suppression
- Improved lipid profile in some studies
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.